This live web event has ended. Thank you for attending.
IGHV Clinical Utility in CLL
and Preferred Testing Practices
Why should you register now for this webinar?
Review the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. Webinar will also provide best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients.
Brought to you by: CAP TODAY; Moderated by: Bob McGonnagle, Publisher, CAP TODAY;
Presenter: Curtis A. Hanson, MD
Describe testing algorithm inclusive of IGHV mutation status determination at initial diagnostic work up for all CLL patients that can support first line treatment decisions, since it is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT)
Show that depending upon a patient’s IGHV mutation status, alternative treatment strategies may be a more suitable option versus CIT
Demonstrate IGHV mutation status testing should be incorporated into comprehensive CLL panels with other important CLL HR prognostic and predictive markers for all newly diagnosed CLL patients
Preferable that IGHV mutation status is determined directly using a molecular method versus indirect Flow or IHC based methods that test surrogate markers.
Ask your questions of our distinguished presenter
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.